🔴 Regeneron Pharmaceuticals is trading 4.49% down in pre-market as no clear company-specific catalyst was identified

Regeneron Pharmaceuticals is trading 4.49% down at $791.27 in pre-market, with no clear August 25, 2026 company-specific catalyst identified.

• The FDA approved Pasatru for fibrodysplasia ossificans progressiva on August 19; the positive announcement was not an evident explanation for the decline.
• Broader markets are higher, so the move does not clearly track overall market sentiment. Reuters reported the approval and its timing.